Format

Send to

Choose Destination
Sci Transl Med. 2017 Jul 5;9(397). pii: eaag0426. doi: 10.1126/scitranslmed.aag0426.

Marketing of unproven stem cell-based interventions: A call to action.

Author information

1
Riken Center for Developmental Biology, 2-2-3 Minatojima Minamimachi, Kobe 650-0047, Japan. sipp@cdb.riken.jp j.rasko@centenary.org.au.
2
Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
3
Global Initiatives, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
4
Riken Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo 103-0027, Japan.
5
Faculty of Law and School of Public Health, 461 Law Centre, University of Alberta, Edmonton, Alberta T6G 2H5, Canada.
6
Department of Public Health, University of Oxford, Oxford, UK.
7
Medical Research Council Centre for Regenerative Medicine, School of Biological Sciences, University of Edinburgh, 5 Little France Drive, Edinburgh EH16 4UU, UK.
8
Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Nine Bioquarter, 9 Little France Road, Edinburgh EH16 4UX, UK.
9
Center for Regenerative Medicine "Stefano Ferrari," Department of Life Sciences, University of Modena and Reggio Emilia, Via G. Gottardi 100, 41125 Modena, Italy.
10
Genetic Alliance UK, Level 3 Barclay House, 37 Queen Square, London WC1N 3BH, UK.
11
Department of Emergency Medicine, University of Alberta, Edmonton, Canada.
12
Centre for Stem Cell Systems, Department of Anatomy and Neuroscience, School of Biomedical Science, Faculty of Medicine, Dentistry and Health Science, University of Melbourne, Level 2, Kenneth Myer Building, 30 Royal Parade Parkville, 3010 Victoria, Australia.
13
Education, Ethics, Law and Community Awareness Unit, Stem Cells Australia, University of Melbourne, Level 2, Kenneth Myer Building, 30 Royal Parade Parkville, 3010 Victoria, Australia.
14
Department of Anthropology, University of Sussex, Brighton BN1 9SJ, UK.
15
Berman Institute of Bioethics and Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
16
University of Antwerp, Faculty of Law, Research Group Government and Law, Venusstraat 23, 2000 Antwerp, Belgium.
17
Johnson Shoyama Graduate School of Public Policy, University of Regina, 110-2 Research Drive, Regina, Saskatchewan S4S 7H1, Canada.
18
Sydney Medical School, University of Sydney, Sydney, Australia. sipp@cdb.riken.jp j.rasko@centenary.org.au.
19
Gene and Stem Cell Therapy Program, Centenary Institute, Sydney, Australia.
20
Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Level 2, Building 89, Missenden Road, Camperdown, New South Wales 2050, Australia.

Abstract

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

PMID:
28679655
DOI:
10.1126/scitranslmed.aag0426
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center